Kargi A - Search Results

1

Celik B, Yalcin AD, Bisgin A, Dimitrakopoulou-Strauss A, Kargi A, Strauss LG. Celik B, et al. Among authors: kargi a. Med Sci Monit. 2013 Oct 21;19:875-82. doi: 10.12659/MSM.889605. Med Sci Monit. 2013. PMID: 24145180 Free PMC article.

2

Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer.

Bisgin A, Kargi A, Yalcin AD, Aydin C, Ekinci D, Savas B, Sanlioglu S. Bisgin A, et al. Among authors: kargi a. BMC Cancer. 2012 Feb 7;12:58. doi: 10.1186/1471-2407-12-58. BMC Cancer. 2012. PMID: 22313795 Free PMC article.

3

Serum-soluble TRAIL levels in patients with severe persistent allergic asthma: its relation to omalizumab treatment.

Yalcin AD, Bisgin A, Kargi A, Gorczynski RM. Yalcin AD, et al. Among authors: kargi a. Med Sci Monit. 2012 Mar;18(3):PI11-5. doi: 10.12659/msm.882504. Med Sci Monit. 2012. PMID: 22367138 Free PMC article.

4

Total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations in patients with severe persistent allergic asthma: its relation to omalizumab treatment.

Yalcin AD, Gorczynski RM, Parlak GE, Kargi A, Bisgin A, Sahin E, Kose S, Gumuslu S. Yalcin AD, et al. Among authors: kargi a. Clin Lab. 2012;58(1-2):89-96. Clin Lab. 2012. PMID: 22372350

5

Systemic levels of ceruloplasmin oxidase activity in allergic asthma and allergic rhinitis.

Yalcin AD, Gumuslu S, Parlak GE, Bisgin A, Yildiz M, Kargi A, Gorczynski RM. Yalcin AD, et al. Among authors: kargi a. Immunopharmacol Immunotoxicol. 2012 Dec;34(6):1047-53. doi: 10.3109/08923973.2012.697902. Epub 2012 Jun 28. Immunopharmacol Immunotoxicol. 2012. PMID: 22737977 Clinical Trial.

6

IL8 and serum soluble TRAIL levels following anti-VEGF monoclonal antibody treatment in patients with metastatic colon cancer.

Kargi A, Yalcin AD, Erin N, Savas B, Polat HH, Gorczynski RM. Kargi A, et al. Clin Lab. 2012;58(5-6):501-5. Clin Lab. 2012. Corrected and republished in: Clin Lab. 2012;58(9-10):1103-7. PMID: 22783581 Corrected and republished.

7

Erratum to "IL8 and serum soluble TRAIL levels following anti-VEGF monoclonal antibody treatment in patients with metastatic colon cancer" [Clin. Lab. 2012; 58:501-505].

Kargi A, Yalcin AD, Erin N, Savas B, Polat HH, Gorczynski RM. Kargi A, et al. Clin Lab. 2012;58(9-10):1103-7. Clin Lab. 2012. PMID: 23163132

8

Interaction of allergic disease and (immune) response to cancer in patient with stage-4 adenocarcinoma of the lung.

Yalcin AD, Kargi A, Savas B, Gorczynski RM. Yalcin AD, et al. Among authors: kargi a. Clin Lab. 2012;58(11-12):1329-30. Clin Lab. 2012. PMID: 23289208

9

The role of VEGF and other parameters in tracking the clinical course in metronomic chemotherapy.

Ekinci D, Kargi A, Yalcin AD, Savas B. Ekinci D, et al. Among authors: kargi a. J BUON. 2013 Jan-Mar;18(1):245-52. J BUON. 2013. PMID: 23613412 Free article.

10

Increased serum S-TRAIL level in newly diagnosed stage-IV lung adenocarcinoma but not squamous cell carcinoma is correlated with age and smoking.

Kargi A, Bisgin A, Yalcin AD, Kargi AB, Sahin E, Gumuslu S. Kargi A, et al. Among authors: kargi ab. Asian Pac J Cancer Prev. 2013;14(8):4819-22. doi: 10.7314/apjcp.2013.14.8.4819. Asian Pac J Cancer Prev. 2013. PMID: 24083751 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

158 results

Search Page

Filters